Form 4 for DXCM Dexcom
Accepted 2022-06-27 00:00:00 ET · period of report 2022-06-23 · accession 0001093557-22-000130 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-27 | 2022-06-23 | DXCM | Pacelli Steven Robert | EVP Managing Dir Dexcom V | S - Sale | $72.55 | -1,000 | 139.7K | -0.7% | -$72.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-23 | S | D | 1,000 | $72.55 | 139,700 | D | — | — | (F1) On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. (F2) Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. |